Results 151 to 160 of about 152,178 (350)

Trastuzumab Deruxtecan for HER2‐Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
ABSTRACT Trastuzumab deruxtecan (T‐DXd) is a third‐generation, HER2‐targeting antibody‐drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have “HER2‐low” (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization‐negative ...
Andrew Redfern, Elgene Lim, Sunil Lakhani, Nirmala Pathmanathan, Sudarsha Selva‐Nayagam, Nicole McCarthy, Belinda Yeo, Benjamin Dessauvagie, Gelareh Farshid   +8 more
wiley   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F. Chen‐Yoshikawa, Yasushi Goto, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu   +9 more
wiley   +1 more source

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer

eLife
Trastuzumab resistance remains a challenge for HER2-positive breast cancer treatment. Targeting metabolic reprogramming would provide novel insights for therapeutic strategies.
Yijia Hua, Ningjun Duan, Chunxiao Sun, Fan Yang, Min Tian, Yanting Sun, Shuhan Zhao, Jue Gong, Qian Liu, Xiang Huang, Yan Liang, Ziyi Fu, Wei Li, Yongmei Yin   +13 more
doaj   +1 more source

EFFECTS OF TRASTUZUMAB ON MYOCARDIAL FUNCTION ON BREAST CANCER PATIENTS

, 2021
Bui Dang Minh Tri, Le Cong Duy Anh, Văn Mãi Đỗ, Nguyễn Hữu Huy Phúc, Nguyen Thi Thuy Linh   +4 more
openalex   +2 more sources

Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2‐Positive Cancers

Cancer Science, EarlyView.
Overexpression of ABC transporters, especially ABCG2 and ABCB1, mediates acquired resistance to T‐DXd in HER2‐positive cancers. Inhibition of these transporters restored T‐DXd efficacy, highlighting efflux‐mediated resistance as a potential therapeutic target. ABSTRACT Antibody–drug conjugates (ADCs) are emerging as a promising class of targeted cancer
Yuya Murase, Shigeki Nanjo, Sachiko Arai, Sota Kondo, Hayato Koba, Yifeng Liu, Koji Fukuda, Shigeki Sato, Jun Kinoshita, Noriyuki Inaki, Tsukasa Ueda, Shunichi Nomura, Yuichi Tambo, Takahiro Shimizu, Masafumi Horie, Daichi Maeda, Richard W. Wong, Kazuyoshi Hosomichi, Takafumi Kobayashi, Satoshi Watanabe, Kenta Yamamura, Noriyuki Ohkura, Miki Abo, Seiji Yano   +23 more
wiley   +1 more source

ITGβ1 (CD29) is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

, 2020
Shahan Mamoor
openalex   +2 more sources

Indium In 111 CHX-A DTPA Trastuzumab [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation [PDF]

, 2023
Douglas M. Dahl, Theodore Karrison, M. Dror Michaelson, Huong Pham, Chin‐Lee Wu, Gregory P. Swanson, William U. Shipley, Jacqueline Vuky, R. Jeffrey Lee, Anthony L. Zietman, Luís Souhami, Brian K. Chang, Richard L. Deming, John Ellerton, Howard M. Sandler, Joseph P. Rodgers, Felix Y. Feng, Jason A. Efstathiou   +17 more
openalex   +1 more source

The fc fragment of IgMs binds C1q to activate the first step of the classical complement pathway, while inhibiting complement‐dependent cytotoxicity

The FEBS Journal, EarlyView.
Multimeric IgM‐fragment crystallizable region (Fc) fragments retain the ability to bind C1q and initiate the classical complement pathway, leading to C4 activation and deposition in vitro. However, the Fc cores can also inhibit complement‐dependent cytotoxicity by competing with surface‐bound antibodies for C1q engagement.
Andrea J. Pinto, Anne Chouquet, Isabelle Bally, Véronique Rossi, Nicole M. Thielens, Chantal Dumestre‐Pérard, Renate Kunert, Christine Gaboriaud, Wai Li Ling, Jean‐Baptiste Reiser   +9 more
wiley   +1 more source

Correlation between resistance to trastuzumab and miR-141 relative expression in the BT-474 human breast cancer cell line

مجله دانشگاه علوم پزشکی بیرجند, 2017
Background and Aim: Resistance to trastuzumab has been a critical barrier to targeted therapy of HER 2-positive (Human Epidermal Growth Factor Receptor 2) breast cancers.
Zohreh Rezaei, Dor Mohammad Kordi-Tamandani, Ahmadreza Sebzari, Kazem Dastjerdi   +3 more
doaj